Displaying items by tag: alabama vaccine research clinic

Researchers hope to learn whether the immune system will respond to the experimental vaccines by making antibodies and T cells that could fight HIV if a person is ever exposed to the virus in the future.

Many Americans say they want to “make sure the shot is safe” before getting vaccinated. That data is already in, and it is overwhelming. 

A groundbreaking clinical research trial at UAB’s Alabama Vaccine Research Clinic to compare injectable PrEP versus a daily oral regimen for HIV prevention is now recruiting participants. 

Antibody VRC01 proves safe for individuals infected with HIV-1 but only modestly controls the virus in participants who stop receiving antiretroviral therapy.
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
An international clinical trial for a new HIV antibody, VRC01 begins in late spring at UAB as part of the Antibody Mediated Prevention study.
UAB is recruiting postpartum women who are still lactating, for a study on the effects of the antiretroviral drug used to prevent HIV transmission.